comparemela.com
Home
Live Updates
Ipsens Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA -February 13, 2024 at 04:09 pm EST : comparemela.com
Ipsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA -February 13, 2024 at 04:09 pm EST
Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and...
Related Keywords
France ,
Taiwan ,
United States ,
San Francisco ,
California ,
Taipei ,
T Ai Pei ,
Australia ,
Paris ,
France General ,
America ,
American ,
Zev Wainberg ,
Julie Fleshman ,
Christelle Huguet ,
Ipsen Euronext ,
Rachel Reiff ,
Drug Administration ,
American Cancer Society ,
Pancreatic Cancer Action Network Pan ,
Head Of Research ,
National Comprehensive Cancer Network ,
Ucla Gi Oncology Program ,
Ipsen Biopharmaceuticals Inc ,
Pancreatic Cancer Action Network ,
National Comprehensive Cancer ,
Ipsen Cares ,
Ipsen Fast Track ,
North America ,
South America ,
Rare Disease ,
Sponsored Leveli American Depositary Receipt ,
Lung Disease ,
Hypersensitivity Reaction ,
Fetal Toxicity ,
Reproductive Potential ,
Ipsen Biopharmaceuticals ,
Prescribing Information ,
French Autorit ,
Des March ,
Universal Registration Document ,
Cancer Society ,
Cancer Facts ,
Open Label Phase ,
Liposomal Irinotecan ,
Metastatic Pancreatic Ductal Adenocarcinoma ,
Cancers Symposium ,
Markets ,
comparemela.com © 2020. All Rights Reserved.